Enterprise Value

149.5M

Cash

13.47M

Avg Qtr Burn

-9.493M

Short % of Float

7.71%

Insider Ownership

36.15%

Institutional Own.

18.96%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Avasopasem Manganese (GC4419) Details
Head and neck cancer, Cancer

Phase 3

Update

Avasopasem Manganese (GC4419) Details
Lung cancer, Esophagitis, Non-small cell lung carcinoma

Phase 2a

Update

Avasopasem Manganese (GC4419) Details
Infectious disease, COVID-19

Failed

Discontinued

Rucosopasem Details
Cancer, Non-small cell lung carcinoma

Failed

Discontinued

Rucosopasem Details
Pancreatic cancer, Cancer

Failed

Discontinued